This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): deferiprone, L1
Description: Ferriprox (deferiprone) is an oral iron chelator.
Deal Structure: BTG, the patent rights holder to deferiprone, granted Apotex the rights to develop the drug.
By June 2008, BMP Sunstone was marketing and distributing Ferriprox in China under its five-year licensing agreement with Apotex.
In November 2010, Sanofi-Aventis announced that it would acquire BMP Sunstone for $520.6 million or $10 per share.
Additional information available to subscribers only: